Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | FABP2 | P12104 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluprofen SCHEMBL29357121 | 1.00 | PTGS2 (0.69) | PTGS2FFAR1AKR1C3AKR1C2PTGS1 | |
| SCHEMBL9981046 | 0.84 | PTGS2 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL4217690 | 0.83 | FFAR1 (0.49) | PTGS2FFAR1PTGS1HPGDMMP1 | |
| SCHEMBL9592228 | 0.83 | PTGS2 (0.71) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL1211557 | 0.82 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL7826539 | 0.82 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL2183822 | 0.81 | PTGS1 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8136361 | 0.81 | PTGS1 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8136359 | 0.81 | PTGS1 (0.59) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| Hydrochloric Acid SCHEMBL5753890 | 0.81 | PTGS2 (0.96) | PTGS2AKR1C3AKR1C2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800179-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3656765-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3653600-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3650439-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3636629-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9133142-B2 | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-2595971-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010316-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2012-01-26 | — | — | WO | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| CN-1530098-A | Topical preparation effective in relieving pain/inflammation caused by herpes virus infection | ����ҩƷ��ҵ�ɷ�����˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | RCC2, EP300, SIGMAR1 | PTGS2 548/4885FFAR1 571/4885AKR1C3 2293/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGS2 2066/4885FFAR1 3064/4885AKR1C3 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.